Statement: Diarrhea was the most common adverse event in cohort 1 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 10/30 (33.33%)   Hemoglobin decreased 2/30 (6.67%)   Abdominal pain 1/30 (3.33%)   Colitis 1/30 (3.33%)   Diarrhea 7/30 (23.33%)   Nausea 2/30 (6.67%)   Rectal hemorrhage 1/30 (3.33%)   Fatigue 1/30 (3.33%)   Skin infection 1/30 (3.33%)   Neutrophil count decreased 1/30 (3.33%)   Platelet count decreased 3/30 (10.00%)   Dehydration 1/30 (3.33%)